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1078–5Carotid disease is like any other atherosclerotic manifestation, a condition, which may induce thrombosis, in this case with
subsequent cerebral ischemia. Carotid endarterectomy has proven effective in preventing ipsilateral stroke, however, the
studies pro-viding the evidence were conducted before the use of statins, newer antiplatelet and antihypertensive drugs,
and at a time when less emphasis was on lifestyle modification. Therefore, it is likely that, not only would all patients
with carotid stenosis benefit from modern medical treatment, in addition, some patients could have similar risk reduction
to that of endarterectomy, were these effective preventive drugs used systematically, as recommended, in this patient group.
This article reviews the evidence that is available concerning medical therapy for patients with carotid stenosis, with
special emphasis on antiplatelet and statin therapy. An example on how this treatment may be organised is given.
 2007 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.
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It is important to recognise that the evidence used to
develop international guidelines for the surgical
treatment of patients with carotid artery disease is
based upon trials that were conducted up to 20 years
ago when the concept of ‘best medical therapy’ was
fairly rudimentary (i.e. essentially ‘stop smoking
and take aspirin’). The two principle symptomatic
trials (NASCET and ECST) randomised patients
throughout the 1980s, reporting their positive results
for the management of severe stenosis in 1991.1,2 The
two trials in asymptomatic patients (ACAS and ACST)
were undertaken in the 1990s and the beginning of
the current century, reporting in 1995 and 2004.3,4What has changed?
During the last 20 years, major advances have been
made regarding medical therapy (antiplatelet, statin,
and hypertension) alongside changes in lifestyle (e.g.sponding author.
address: henrik.sillesen@rh.dk
884/000139 + 06 $34.00/0  2007 Published by Elsevier Ltd ongreater emphasis on smoking cessation). These have
to be considered when planning the management of
patients with carotid disease. For example, it is an in-
disputable fact that hypertension is now managed
much better than 20 years ago with treatment goals
set at stricter blood pressure thresholds than those ad-
vocated in the 1980s. Statin therapy, perhaps the single
most important pharmacological advance in cardio-
vascular risk factor management was not available
when ECST, NASCET and ACAS were recruiting.
Even in the recently published ACST trial, only 30%
of patients were on statin therapy when they were
randomised.4 Third, there are now several new classes
of antiplatelet agent some of which when adminis-
tered as ‘dual’ therapy confer enhanced benefit. Ac-
cordingly, not only is there is the potential for
offering improved antiplatelet activity, but there are
now also therapeutic alternatives to the 10% of pa-
tients with aspirin intolerance or resistance.Rapid access ‘best medical therapy’?
Emerging evidence suggests that carotid endarterec-
tomy (CEA) confers maximum benefit if it is per-
formed within 2 weeks of onset of symptoms.5behalf of European Society for Vascular Surgery.
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rapid implementation of ‘best medical therapy’ could
have just as beneficial an effect. This is largely because
most clinicians believe that there is an inevitable ‘lag
phase’ (lasting many months) before medical therapy
can take effect. The potential importance of starting
medical therapy as soon as possible was highlighted
in the recently published Express Study.6 Here, the
90-day stroke rate was reduced from 10.2% to 2.1%
as a consequence of simply changing clinical practices
so as to minimise delays in assessment, investigation
and treatment of patients with symptomatic cerebral
vascular disease (Fig. 1). Medical therapy (aggressive
antiplatelet, statin and anti-hypertensive therapy) was
instituted in the majority of cases within 24 hours of
onset of symptoms. Although this strategy also re-
duced delays to CEA, approximately 85% of the ob-
served reduction in recurrent stroke was attributed
to the fact that ‘best medical therapy’ had been insti-
tuted as soon as possible.6Surgeons and ‘best medical therapy’
Why is it so important for the vascular surgeon/spe-
cialist to be aware of the value of improvements in
medical therapy in patients with carotid stenosis?
First of all, having any kind of atherosclerotic disease
(coronary, cerebrovascular, renovascular, mesenteric
or peripheral) indicates that there is a systemic effect
on the arterial system. In other words, the patient
with carotid disease is not only at risk of stroke but
also of myocardial infarction and other ischemic com-
plications. In reality, the annual risk of death/myocar-
dial infarction is much higher than that of ipsilateral
stroke in patients with asymptomatic carotid stenosis.1,2,70
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Fig. 1. 90 day risk of stroke following presentation of initial
TIA or stroke. ‘‘Before’’ Refers to previous treatment algo-
rithm, ‘‘After’’ refers to new practice to expedite assess-
ment and start ‘best medical treatment’.
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lar death, myocardial infarction & stroke) may be as
high as 7e10% per year or more.8 Put simply, it is
no use simply treating a carotid stenosis by surgery
or angioplasty to the exclusion of all other aspects
of care.
‘‘Best medical treatment’’ can be an overused and
over-simplified term. This paper will review new
and emerging data from the literature, predomi-
nantly relating to antiplatelet and statin therapy.
All of the data and recommendations regarding
medical therapy in patients with carotid disease
are derived from general studies on stroke preven-
tion, atherosclerosis prevention and (wherever possi-
ble) primary and secondary analyses from stroke
prevention studies involving patients with carotid
disease.Antiplatelet Therapy
(1) Symptomatic patients with carotid stenosis
Aspirin has been shown to reduce the risk of stroke in
patients with previous cerebrovascular symptoms
(TIA or stroke). The latest meta-analysis from the
Anti-thrombotic Trialists Collaboration reviewed 21
placebo controlled trials (including more than 22,000
patients with previous stroke or TIA) and found that
treatment with an anti-platelet agent resulted in
a 22% relative risk reduction (RRR) in the combined
end-point of vascular death, myocardial infarction
and stroke.9 Fig. 2 summarises the principle benefits
conferred by three years of antiplatelet therapy in pa-
tients who had initially presented with TIA or stroke.
This meta-analysis also reviewed studies looking at
different aspirin doses and observed that 75e150 mg
daily was just as effective as higher doses, but with
fewer side effects.
Several contemporary studies have also evaluated
the role of alternative and/or dual antiplatelet ther-
apy regimes. The CAPRIE Study compared aspirin
75 mg daily with clopidogrel 75 mg daily.10 This trial
randomised more than 19,000 patients with athero-
sclerotic disease and demonstrated an 8.7% RRR in
the combined endpoint of vascular death, myocardial
infarction and stroke favouring clopidogrel. The ben-
efit in the subset of patients with a prior history of
cerebrovascular disease was similar to that of the
overall, intention-to-treat population. Interestingly,
patients who at randomisation had reported symp-
toms from more than one vascular territory (e.g. coro-
nary, cerebrovascular and/or peripheral arterial)
appeared to gain greater benefit (22% RRR).
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Fig. 2. Effect of antiplatelet agents on non-fatal myocardial
infarction (MI), non-fatal stroke, vascular death and any
death in patients with previous stroke or TIA. Bars indicate
incidence in percent (mean duration of treatment 3 years).9
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aspirin to placebo, dipyridamole to placebo, aspir-
inþ dipyridamole to placebo and aspirin alone in pa-
tients with recent stroke or TIA.11 Aspirin on its own
conferred an RRR of 18% in late stroke, as compared
with 16% for dipyridamole alone. The maximum ben-
efit, however, was seen in patients randomised to
combination therapy (RRR in stroke¼ 37%).
The CHARISMA trial compared Aspirin and
Clopidogrel against aspirin alone in patients with
symptomatic atherosclerotic disease and those
asymptomatic patients with risk factors.12 Analysing
all of the patients on an intention-to-treat basis
showed a non-significant 7% RRR in the risk of future
ischemic events (death, myocardial infarction, and
stroke). However, a secondary analysis comprising
only symptomatic patients from CHARISMA re-
vealed a 12% RRR in favour of combination therapy
which just reached statistical significance.
Based on the available evidence in symptomatic
patients (and without knowledge of whether they
did or did not have carotid stenosis), the following
recommendations can be made with reasonable cer-
tainty in symptomatic patients:
1. Antiplatelet agents are proven to be beneficial for
patients with previous cerebrovascular disease. It
should, therefore, be assumed that this finding
also holds true for symptomatic patients with ca-
rotid stenosis.
2. There may be differences in the benefit conferred by
individual antiplatelet agents. Clopidogrel is a more
potent antiplatelet agent than aspirin but due con-
sideration must also be given to the risk of excess
bleeding should the patient require surgery.
3. Low dose aspirin therapy is just as effective as
high-dose aspirin.4. Combination therapy (aspirin plus dipyridamole or
aspirin plus clopidogrel) may increase the overall
benefit, especially in patients not being considered
for surgery or angioplasty.
(2) Asymptomatic patients with carotid stenosis
It is much more difficult to make recommendations
based on evidence in this category of patient as they
have never been subjected to scientific scrutiny. Ac-
cordingly, some have suggested that primary prophy-
laxis (with aspirin) may not be appropriate in every
patient because the prevalence of side-effects may
outweigh any clinical benefit.13 However, patients
with asymptomatic carotid disease have proven ath-
erosclerosis and a rate of ischemic events that exceeds
the rate observed in persons without carotid disease.7
The European Stroke Initiative currently recommends
anti-platelet therapy in patients with asymptomatic
carotid disease (primarily) for the prevention of
cardiac events.14Statin Therapy
The SPARCL Trial, which randomised 4732 patients
with recent stroke or TIA to atorvastatin 80 mg per
day or placebo, reported a 16% reduction in the risk
of future stroke.15 A subgroup analysis from the
SPARCL study looked at the effect of statin in 1007 pa-
tients with a documented carotid stenosis.8 Here they
observed a 33% RRR in the risk of late stroke, a 42%
RRR in major coronary events and a 56% reduction
in the need for carotid revascularisation in the group
taking 80 mg atorvastatin.8
Unlike the Express study summarised earlier,
SPARCL was not an ‘acute’ study. Patients were eligi-
ble for entry if they had had suffered a TIA/stroke
within 1 to 6 months.15 In fact, the average time
from ischemic event to randomisation was 90 days.
When one considers that the 30-day recurrent stroke
rate is approximately 10% in patients with an ipsilat-
eral carotid stenosis, many potentially eligible pa-
tients would have suffered their stroke before
entering the trial. The question therefore remains;
how much more benefit would have accrued had
the patients been recruited earlier.
Although not a stroke trial, the MIRACL Study pro-
vides further support for rapid intervention with sta-
tin therapy. In this study, patients who presented
with an acute coronary syndrome (ACS) were rando-
mised to atorvastatin 80 mg or placebo within 24e48
hours.20 By sixteen weeks, aggressive early treatmentEur J Vasc Endovasc Surg Vol 35, February 2008
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secondary coronary events.16
The Heart Protection Study (HPS randomised pa-
tients to simvastatin 40 mg or placebo and showed
that in patients with a history of prior cerebrovascular
symptoms, statin therapy conferred a 23.6% RRR in
the composite endpoint of vascular death, myocardial
infarction, stroke and need for revascularisation.17
However, the incidence of late stroke (alone) was
not reduced by statin therapy and it is possible that
these patients probably gained more benefit from car-
diac protection. An alternative explanation for this
otherwise unexpected finding may be the fact that pa-
tients were randomised (on average) 4.3 years after
the qualifying event.
Accordingly, in symptomatic patients with carotid
disease, there is compelling evidence for starting sta-
tin therapy as soon as possible. However, is there
a cholesterol level below which statins do not work?
Are there some patients who do not need the drug?
There is accumulating evidence that the lower the
cholesterol level (while on statin therapy), the fewer
the atherosclerotic complications and this is NOT at
the expense of a higher prevalence of serious side ef-
fects.15,18e20 In SPARCL, the mean on treatment LDL
cholesterol level throughout the 5 years of the trial
was 73 mg/dl (1.8 mmol/l) with no difference being
observed in the prevalence of adverse effects between
the treatment and placebo groups. In the TNT trial
(which included 10,000 patients with stable ischaemic
heart disease), the maximum overall benefit conferred
by statin therapy was observed in the quintile of pa-
tients recording the lowest LDL (mean LDL choles-
terol of 53 mg/dl (1.3 mmol/l)) but without an
increase in clinical side effects.18
For patients with asymptomatic carotid disease
there are no data from large randomised trials in
asymptomatic patients to guide practice. However,
the European Stroke Initiative have recommended
that statin therapy be implemented in patients with
asymptomatic carotid disease unless contraindicated.14
Ongoing research will report whether Ezetimbe
(a novel agent, for inhibiting cholesterol absorption
from the intestine) confers a significant reduction in
stroke risk, while drugs designed to increase HDL
cholesterol are under development. At present, there
are no data to support the preferential use of these
agents over statins (Table 1).Antihypertensive Therapy
It is beyond the scope of this paper to overview the
randomised trials testing different antihypertensiveEur J Vasc Endovasc Surg Vol 35, February 2008drugs and how to initiate and titrate treatment.
The reader is advised to consult the European Guide-
lines which otherwise provide a comprehensive
review of the literature.21 In summary, however, con-
trol of hypertension remains one of the cornerstones
of risk-factor management and blood pressure should
(preferably) be maintained <140/90 mmHg for non-
diabetic patients with carotid stenosis and <130/
80 mmHg for patients with diabetes.
There is emerging evidence that some antihyper-
tensive medications may exert their beneficial effect
in ways other than by reducing blood pressure. In
the HOPE Study, it was observed that a daily 5 mg
dose of Ramipril (which did not really alter blood
pressure) conferred a significant reduction in the
risk of late ischemic events.22 Subsequent studies
showed that patients with peripheral arterial disease
appeared to benefit more than others.23 More recently,
the latest class of drugs working on the renin-angio-
tensin system seem to offer more benefit than that
conferred by betablockers for the same reduction in
blood pressure. It is conceded, however, that 74% of
the patients randomised in this trial did not have
symptomatic atherosclerotic disease24 and it is there-
fore difficult to know whether the same applies in
patients with carotid disease.Diabetes
Diabetes is another major risk factor for vascular dis-
ease whose management is again outwith the scope of
this article.25 Interestingly, tight glycaemic control
does not seem to reduce the long term risk of stroke
but meticulous attention to risk factor control (espe-
cially hypertension) has been proven to reduce the
risk of late stroke by 40%.26
Life Style Changes
Smoking, physical inactivity and eating habits are
important risk factors for the development of vascular
disease. It is very important to understand that al-
though preventive medications are easy to prescribe,
modification of lifestyle is equally important in order
to reduce the risk of stroke in patients with carotid
artery disease.How to provide secondary prevention
There are many types of lifestyle clinic, most linked
with a service to ensure that ‘best medical therapy’
is also delivered to the patient. The following is a
Table 1. Summary of recommendations for ‘best medical therapy’ in patients with asymptomatic and symptomatic carotid disease
derived from the European Stroke Initiative14
Treatment Asymptomatic Symptomatic
BP< 140/90 mmHg or <130/80 mmHg in diabetics Level I Level I
Glycaemic control to prevent other diabetic complications Level III Level III
Statin therapy Level I Level I
Stop smoking Level II Level II
Avoid heavy consumption of alcohol Level I Level I
Regular physical activity Level II Level II
Low salt, low saturated fat, high fruit and vegetable diet rich in fibre Level II Level II
If BMI elevated, reduce weight Level II Level II
HRT should not be used for stroke prevention in women Level I Level I
Aspirin To prevent MI level IV Level I
Aspirin & Dipyridamole Not recommended level IV Level I
Clopidogrel Not recommended level IV Level I
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plemented in Copenhagen. As will be seen it involves
close co-operation between nurses and vascular
surgeons.
The typical patient course is as follows. A newly
referred patient with stroke/TIA (or aneurismal/
peripheral vascular disease) is seen by a consultant
who evaluates the patient’s symptoms and considers
whether an intervention is appropriate. Irrespective
of this judgement, the patient’s medication is re-
viewed. The nurses ensure that all patients are pre-
scribed at least 40 mg simvastatin and 75 mg of
aspirin. If the patient has high levels of LDL choles-
terol a more potent statin may be used from the out-
set. The patient is then questioned about life style
and given information about which modifications
should be made. Thereafter, a decision is made as to
whether the patient would benefit from our attending
the rehabilitation clinic. This will obviously depend
on which medical disciplines are already involved.
For example, most diabetic/cardiac patients already
attend specialist clinics and risk-factor control etc
can therefore be devolved to them, thus avoiding du-
plication of effort. However, if the patient is not at-
tending other clinics and if the patient is motivated,
he/she is offered the chance to participate. This initia-
tive involves a minimum of 4 visits including one at 6
weeks, 3 months, 6 months and then 1 year. On each
occasion, smoking cessation advice is given and med-
ical therapy reviewed. If blood tests show a need for
an increase in dose or a change in the type of statin,
the clinic nurse ensures that this happens. Using this
approach, approximately 90% of patients will be tak-
ing platelet inhibitors and statins by the 2nd visit
and cholesterol levels are (on average) 0.5 mmol/l
below national treatment targets which means that
approximately 80% of patients are reaching their tar-
get. A fuller description of the methodology and re-
sults from this lifestyle service has been described in
detail elsewhere.27How might new improvements in ‘best medical therapy’
affect the evidence from the surgical trials upon which
we currently base management decisions?
As mentioned in the introduction, the trials that estab-
lished that CEA conferred significant benefit were
largely undertaken in an era when much of what
now constitutes ‘best medical therapy’ was unavail-
able. Accordingly, it might not be unreasonable to
speculate that were the trials to be repeated, the num-
ber of strokes observed in the medical limb of the tri-
als would be significantly fewer. Accordingly, if one
assumed that improved, modern medical care re-
sulted in a 40% RRR in the risks of stroke observed
in the medical limbs of the symptomatic and asymp-
tomatic trials, most of the significant benefits con-
ferred by CEA would probably disappear. This 40%
figure is not unreasonable as statin therapy alone
might be expected to confer a 30% RRR in the rates
of stroke observed 20 years ago.
As a consequence, the available evidence from
ECST, NASCET, ACAS and ACST is outdated and it
is inappropriate to continue to uncritically extrapolate
data to justify practice in the modern era. To this
author, at least, any new trial comparing CEA with
angioplasty (especially in asymptomatic patients)
should also include a medical treatment limb.
Conclusion
The concept of ‘best medical therapy’ has advanced
dramatically over the last two decades and requires
all of us to enforce lifestyle modification, (dual) anti-
platelet and statin therapy in practically all of our
patients along with meticulous attention to blood
pressure control especially in diabetics. Since there
does not seem to be a lower cholesterol value below
which statins cease to confer benefit, aggressive lipid
lowering therapy is probably beneficial in almost
every patient with a carotid stenosis.Eur J Vasc Endovasc Surg Vol 35, February 2008
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